Summit Therapeutics (SMMT) EBIT Margin (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly EBIT Margin came in at 7700.0% in Q3 2022, down 621138.0% YoY from N/an in Q3 2021, and down 42.57% on a QoQ basis from 5400.85% in Q2 2022.
Summit Therapeutics (SMMT) EBIT Margin (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of EBIT Margin data on file, last reported at 7700.0% in Q3 2022.
- Quarterly EBIT Margin fell 621138.0% year-over-year to 7700.0% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 268266.82% (down 26433611.0% YoY) and the FY2022 annual result came in at 10225.39%, down 546110.0% from the prior year.
- EBIT Margin retreated to 7700.0% in Q3 2022, from 5400.85% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 76.39% in Q4 2019 to a low of 41631.58% in Q2 2021.
- A 5-year average of 7865.06% and a median of 6328.1% in 2020 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2021 — EBIT Margin sank 3259864 bps — and 2022, when it soared 3623073 bps.
- Tracing SMMT's EBIT Margin over 5 years: stood at 3288.59% in 2018, then soared by 102 bps to 76.39% in 2019, then plunged by 8277 bps to 6246.49% in 2020, then plunged by 66 bps to 10377.29% in 2021, then grew by 26 bps to 7700.0% in 2022.
- The last three EBIT Margin figures came in at 7700.0% (Q3 2022), 5400.85% (Q2 2022), and 8863.2% (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -7,700.00% |
| Jun 30, 2022 | -5,400.85% |
| Mar 31, 2022 | -8,863.20% |
| Dec 31, 2021 | -10,377.29% |
| Sep 30, 2021 | -1,488.62% |
| Jun 30, 2021 | -41,631.58% |
| Mar 31, 2021 | -8,814.06% |
| Dec 31, 2020 | -6,246.49% |
| Sep 30, 2020 | -9,359.67% |
| Jun 30, 2020 | -9,032.94% |
| Mar 31, 2020 | -6,409.72% |
| Dec 31, 2019 | 76.39% |
| Oct 31, 2019 | -15,553.23% |
| Sep 30, 2019 | -4,182.43% |
| Jul 31, 2019 | -13,157.94% |
| Mar 31, 2019 | -4,578.93% |
| Oct 31, 2018 | -3,288.59% |
| Jul 31, 2018 | 21.93% |
| Apr 30, 2018 | -529.35% |
| Jan 31, 2018 | -784.70% |